Subscribe To
89bio's low price presents an opportunity
89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive ...
October 26, 2023, 2:15 pm
89bio earns ‘buy' rating in initial coverage on positive prospects for nash therapeutic
Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th...
August 28, 2023, 3:01 pm
89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and ...
June 24, 2023, 9:05 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week d...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week d...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week d...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week d...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week d...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week d...
June 24, 2023, 9:01 am
89bio shares rise as analysts see improved outlook for nash treatments
Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the...
June 13, 2023, 8:29 am
Why shares of 89bio soared this week
89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH dru...
March 24, 2023, 10:57 am
Biotech stock surges on mid-stage drug trial success
The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug ...
March 22, 2023, 10:49 am
Why is 89bio (etnb) stock up 34% today?
89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to d...
March 22, 2023, 9:30 am
89bio: a promising nash innovator
As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer a...
March 17, 2023, 6:18 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and ...
March 4, 2023, 6:30 pm
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am